摘要
本研究以乙型肝炎病毒脱氧核糖核酸（ＨＢＶＤＮＡ）转染细胞系（２．２．１５细胞株）为模型，对复方华蟾素口服液体外抗乙型肝炎病毒（ＨＢＶ）活性进行了研究。结果显示：该药对乙型肝炎表面抗原（ＨＢｓＡｇ）和乙型肝炎ｅ抗原（ＨＢｅＡｇ）半数抑制剂量（ＩＤ５０）分别为０．０８ｍｇ／ｍｌ和０．０７ｍｇ／ｍｌ，半数中毒剂量（ＣＤ５０）为２．５ｍｇ／ｍｌ，治疗指数（ＴＩ）分别为ＨＢｓＡｇ３１．３、ＨＢｅＡｇ３５．７，提示该药体外有良好的抗ＨＢＶ活性。Ｓｏｕｔｈｅｒｎ印迹杂交显示：复方华蟾素口服液对细胞内ＨＢＶＤＮＡ及其复制中间体呈剂量依赖型抑制。
Co-Cinobufotalin Oral Liquor (CCOL) was studied for its ability to inhibit hepatitis B virus DNA replication, HBsAg and HBeAg expression in a HBV-transfected cell line(2.2.15 cell).The result showed that ID50(the drug concentration that inhibits HBsAg or HBeAg secretion by 50%)was 0.08 mg/ml and 0.07 mg/ml on HBsAg and HBeAg respectively. CD50(the drug concentration that reduces cell growth by 50%) was 2.5 mg/ml.TI(therapeutic index)was 31.3 and 35.7 respectively.The present data suggest that CCOL could exert a potent antiviral activity against HBV in vitro.Southern blot showed that CCOL inhibited HBV-DNA replication in a dose-dependent manner.
出处
《中国中西医结合杂志》
CAS
CSCD
北大核心
1996年第12期738-740,共3页
Chinese Journal of Integrated Traditional and Western Medicine
关键词
乙型肝炎病毒
复方华蟾素
口服液
中医药疗法
hepatitis B virus,transfected cell line,Co-Cinobufotalin Oral Liquor,Southern blot hybridization
